Adverse Event Management Aesthetic Consultation

Categorising Adverse Events

Adverse events in aesthetic treatments fall into broadly three categories: expected post treatment effects, common side effects, and uncommon complications. Each is managed differently.

Expected post treatment effects include short term swelling, mild bruising, tenderness at injection sites, and minor redness. These are part of the normal healing response and resolve over days. They are discussed at consultation as part of informed consent. They do not require active intervention beyond standard aftercare.

Common side effects include more pronounced bruising, prolonged swelling, asymmetry that resolves with settling, palpable lumps from volume treatment that smooth with massage, and minor headache after wrinkle treatment. These are managed through patient education, scheduled review, and conservative intervention where indicated.

Uncommon complications include vascular events from treatment placement, allergic reactions, infection, prolonged or unexpected weakness from wrinkle treatment in adjacent muscles, and granuloma formation. These require defined protocols, urgent contact pathways, and in some cases referral to other healthcare providers.

Pretreatment Risk Reduction

The strongest predictor of adverse events is what happens before the injection, not after. Risk is reduced through structured pretreatment assessment that identifies patients for whom treatment carries higher risk and either modifies the plan or defers treatment entirely.

Medical history screening identifies medications that increase bleeding risk (anticoagulants, certain anti inflammatories), conditions that affect healing (autoimmune disease, immunosuppression), recent dental work or skin infection that may seed bacteria, history of allergic reaction to injectable products, pregnancy or breastfeeding (a contraindication for elective aesthetic treatment), and any neuromuscular condition that affects how the patient responds to wrinkle treatment.

Anatomical assessment identifies anatomical features that affect injection technique: visible vasculature, prior surgical history, asymmetry, scar tissue, and dental anatomy that affects jaw muscle or chin treatment. Patients are screened against contraindications. Where contraindications are present, the appropriate response is to defer or decline treatment, not to proceed with caution.

Informed Consent as Part of Safety

Informed consent is a safety mechanism, not a paperwork step. Consent involves a documented conversation that confirms the patient understands what will be injected, where, why, what the expected outcome is, what the known risks are at general and product specific level, what to do if a complication is suspected, and what alternatives are available including the alternative of no treatment.

The consent conversation is renewed at every appointment. A patient who has had treatment before still receives the consent conversation for the current treatment, because consent is specific to the planned intervention. Where any new factor is present (medication change, recent illness, new pregnancy possibility) the consent process surfaces it before treatment.

Documented consent supports patient autonomy and provides the audit trail required by AHPRA. It also ensures that if an adverse event occurs, the patient already understands the protocol for contacting the clinic and what response to expect.

In-Treatment Recognition

Adverse events that develop during treatment are managed in real time. The practitioner monitors injection sites for unexpected blanching of the skin (which may indicate compression of a blood vessel), unusual pain that does not match the expected sensation, sudden colour change in the surrounding tissue, or delayed capillary refill at the treated area.

If any of these signs is observed, the injection is stopped immediately and the situation is assessed. The response depends on what is observed. For suspected vascular compromise from volume treatment, the protocol involves immediate cessation, application of warmth to encourage vasodilation, and consideration of dissolving agent depending on the area and timing.

This is one reason consultation based, one practitioner care matters for safety. The practitioner knows the patient’s baseline anatomy, has time to monitor during injection, and has the autonomy to stop and reassess at any point. High volume environments where injections are delivered rapidly have less of this monitoring time built into the workflow.

Post-Treatment Patient Communication

Patients leave each appointment with written aftercare information specific to the treatment received and a direct contact pathway for any post treatment concerns. The aftercare information explains what is expected (mild swelling, bruising, tenderness) and what is not expected and warrants contact (severe pain, unilateral colour change, vision changes, unexpected weakness in adjacent areas, signs of infection).

The contact pathway is direct to the practitioner during clinic hours and includes after hours instructions for urgent concerns. Patients are told that contacting the clinic about a concern is appropriate even if the concern turns out to be a normal part of recovery. The clinic prefers to assess a normal recovery than to miss an early sign of complication.

For wrinkle treatment, scheduled review at two weeks provides a structured opportunity to identify asymmetry, ptosis, or other delayed effects. For volume treatment, review timing depends on the area treated and the question being assessed.

Vascular Events: The Highest-Priority Complication

Vascular compromise is the most serious complication of facial volume treatment. It occurs when volume treatment is injected into or compresses a blood vessel, restricting blood supply to the surrounding tissue. The signs include unexpected blanching, severe pain that does not match the expected sensation, and dusky or mottled skin colouration.

Management requires immediate cessation, application of warmth, and consideration of hyaluronidase (the dissolving agent for hyaluronic acid volume treatment) to break down the obstructing material. The response is time sensitive. Recognition within minutes to hours significantly improves the outcome compared to delayed recognition.

This is the reason the practitioner monitors closely during injection, the reason injection technique emphasises slow placement and aspiration where appropriate, the reason patients are told what to watch for after leaving the clinic, and the reason direct contact is available outside scheduled appointments. The probability of a vascular event is low when conservative technique is used, but the consequence makes it the highest priority complication to prepare for.

Wrinkle Treatment: Specific Adverse Effects

Wrinkle treatment has its own profile of potential adverse effects. The most discussed is unintended weakness in adjacent muscles, sometimes described as ‘spread’ or ‘diffusion’. This can produce eyelid ptosis, brow asymmetry, or unintended changes in expression.

The risk is reduced by careful injection technique, appropriate dosing, anatomical knowledge of muscle origins and insertions, and patient instruction about post treatment activity (avoiding rubbing the area, avoiding pressure or strenuous exercise for several hours).

Where unintended effects occur, they are time limited. wrinkle products metabolise and the effect resolves over weeks. Management includes patient reassurance, monitoring at review, and in some cases prescription adjuncts (eye drops for ptosis) to manage symptoms while the effect resolves. The two week review is the structured point at which any unintended effect is identified and managed.

Infection: Prevention and Recognition

Infection at injection sites is rare when sterile technique is used but is not impossible. Prevention starts with appropriate skin preparation, single use sterile equipment, careful storage and handling of products, and patient education about avoiding contamination of injection sites for the immediate post treatment period.

Recognition relies on the patient knowing what is normal and what is not. Mild redness, warmth, and tenderness at injection sites for 24 to 48 hours is part of normal healing. Persistent or worsening redness, increasing pain, swelling that develops days after treatment, fever, or pus discharge are signs of infection and warrant urgent contact.

Management depends on the clinical picture. Mild infections may resolve with oral antibiotics. More serious infections may require referral. The patient’s medical history (diabetes, immunosuppression, recent illness) influences both the risk and the response. Patients are told to contact the clinic at the first sign of suspected infection rather than waiting to see if it resolves.

Granuloma and Late-Onset Complications

Some complications develop weeks to months after treatment. Granulomas are tissue reactions to volume treatment material, presenting as firm nodules at injection sites that may be tender, may grow over time, or may be asymptomatic. They are uncommon and may be associated with underlying immune triggers, infection, or product specific factors.

Late onset complications also include delayed inflammation following an unrelated illness or vaccination, where the immune system response affects the treated area. These are unpredictable and not specific to the practitioner’s technique.

Management depends on the clinical presentation. Some granulomas resolve with conservative management. Others require steroid injection, dissolving agent, or referral. The patient is told that contact is appropriate at any time after treatment if a new lump, persistent change, or unexpected symptom develops, even months later.

Documentation and Reporting

Adverse events are documented in the clinical record. The documentation includes the date and nature of the event, the response taken, the outcome, and any communication with the patient or external healthcare providers. This record is part of the clinical audit trail required by AHPRA and is essential for continuity of care.

Serious adverse events may be reportable to the TGA under the medical device or therapeutic product reporting requirements, depending on the nature of the event and the product involved. Where a reportable event has occurred, the practitioner makes the report and informs the patient.

Documentation also supports practice improvement. Reviewing patterns across cases identifies whether technique adjustment, product selection, or screening protocols need refinement. This is part of the practitioner’s continuing professional development obligations.

Patient Responsibilities in Reducing Risk

Patients have a role in reducing adverse event risk. The most important contributions are: complete and accurate medical history disclosure at consultation, declaring any new medications or conditions before each appointment, following pretreatment instructions (avoiding alcohol and certain medications where advised), following aftercare instructions, and contacting the clinic promptly if anything unexpected develops.

Patients are encouraged to ask questions at any point. A patient who is uncertain about whether something they are experiencing is normal should contact the clinic for assessment. The clinic prefers to provide reassurance about a normal symptom than to miss an early sign of complication.

The consultation includes a discussion of the patient’s role in safety. This is part of informed consent and supports the partnership between practitioner and patient that underpins good outcomes.

How This Operates at Core Aesthetics

Core Aesthetics operates with defined adverse event protocols developed and maintained by Corey Anderson, AHPRA registered nurse with specialist focus in aesthetic treatments. The clinic carries dissolving agent on site for volume treatment related events, maintains current emergency response capability, and has documented escalation pathways for events requiring referral.

All patients receive direct contact information at every appointment. After hours instructions cover urgent concerns. Scheduled reviews are part of standard treatment plans. The one practitioner model means the same person who performed the treatment is the one available for any subsequent concern, supporting continuity and accurate clinical reasoning.

The scope of practice is intentionally narrow. Aesthetic treatments only, no laser or device work. This focus supports the depth of preparation required to manage the specific adverse events associated with injectable treatment.

Clinical accountability and how this preparation guide is reviewed

The pretreatment guidance in “Adverse Event Management in Aesthetic treatments: Preparation, Recognition, Response” reflects how Corey Anderson, AHPRA registered nurse (NMW0001047575), prepares patients during the consultation phase at Core Aesthetics. Preparation matters more than most patients realise. Many of the variables that shape the day of treatment experience, bleeding tendency, hydration, skin condition, medication interactions, are decided in the days before the appointment, not on the chair. Results vary between individuals, but preparation reduces the variability that’s within a patient’s control. The recommendations on this page are framed around what an AHPRA-regulated practitioner can and cannot tell a patient to do, and what the published evidence supports for aesthetic treatment preparation.

Specific to adverse event management aesthetic treatments: the timing windows on this page are typical, not absolute. Some patients metabolise medications, alcohol, or supplements faster or slower than the average, body composition, age, liver function, and concurrent prescriptions all matter. Patients on prescription anticoagulants must not stop them before cosmetic treatment without checking with their prescribing doctor first; the bleeding risk from aesthetic treatments is far smaller than the clotting risk from stopping anticoagulation unsupervised. The patient safety aesthetic treatments page covers adjacent considerations in more detail.

Patients reading this page who want to verify Corey Anderson’s AHPRA registration can do so directly on the AHPRA public register at ahpra.gov.au using registration number NMW0001047575. The Core Aesthetics clinic operates from 12A Atherton Road, Oakleigh VIC 3166, Tuesday to Saturday, by consultation appointment. All new patient treatment at Core Aesthetics follows a structured clinical consultation, consistent with the September 2025 AHPRA cosmetic procedures guidelines. Treatment may be scheduled for the same day as consultation or at a subsequent appointment, depending on clinical assessment and individual circumstances. Patients with questions about the content on this page can raise them at consultation; the practitioner is happy to walk through any clinical reasoning that the written content does not fully capture. Results vary between individuals, and the consultation is the appropriate place to discuss what those individual variations mean for a specific person’s treatment plan.

One additional point on preparation: arriving to the appointment relaxed and well hydrated reliably improves the experience. Patients who arrive anxious, hungry, dehydrated, or running late often find the procedure itself more uncomfortable than it needs to be, not because the treatment is different, but because the body’s autonomic state is different. The clinic builds buffer time into the schedule so patients who arrive anxious can settle before treatment begins. Patients researching the topic in more depth may find the cosmetic treatment planning consultation page and the consultation guide Melbourne page useful as further reading; both are written and reviewed under the same clinical accountability framework as this page.